GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

(Alliance News) - GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemotherapy, to include all adult patients with primary advanced or ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

GSK (GSK) and the University of Oxford announced that they have entered a new research collaboration focused on the potential of cancer ...

Bullish option flow detected in GSK (GSK) Pharma with 3,057 calls trading, 1.1x expected, and implied vol increasing over 4 points to 29.80%. Feb-25 34 calls and 1/31 weekly 34 calls are the most ...

Pharmaceutical company GSK PLC is set to move its global headquarters back to central London, ending more than two de ... Subscribe now to see this Premium News article from Alliance News ...